Varex Imaging Corporation VREX R2KR3KPHARMA
Company Overview
Varex Imaging Corporation designs, manufactures, and sells X-ray imaging components. It operates through two segments, Medical and Industrial. The Medical segment designs, manufactures, sells, and services X-ray imaging components, comprising X-ray tubes, digital detectors and accessories, ionization chambers, high voltage connectors, image-processing software and workstations, 3D reconstruction software, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, and heat exchangers. This segment's products are used in a range of applications, including CT, mammography, oncology, cardiac, surgery, dental, and other diagnostic radiography uses. The Industrial segment designs, develops, manufactures, sells, and services Linatron X-ray linear accelerators, non-intrusive cargo inspection systems, X-ray tubes, digital detectors, high voltage connectors, and coolers for use in security and inspection applications, such as baggage screening at airports, cargo screening at ports and borders, and nondestructive testing, irradiation, and inspection in various applications. It sells its products through imaging system original equipment manufacturers, independent service companies, and distributors, as well as directly to end-users. The company has operations in North America, Latin America, Europe, the Middle East, India, Africa, Asia, and Australia. The company was incorporated in 2016 and is headquartered in Salt Lake City, Utah.
Recent Developments
- Oct 2025 Revenue of $844.60M (+0.0% YoY); net profit $-70.30M.
- Trailing 12 Months Year-on-year growth — revenue +3.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 2.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 2.67% |
| 1 Year: | 3.70% |
Stock Price Performance
| 1 Year: | +72.31% |
| 6 Months: | +47.01% |
| 3 Months: | +67.76% |
| 1 Month: | -0.27% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)61.10 · Neutral
P/E of 34.75 is above the sector median of 25.45 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VREX Varex Imaging Corporation R2KR3KPHARMA | 18.42 | 34.75 | $776.37M | 0.00% | -3.02% | 4.59% | 2.67% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jan 2016 | Apr 2016 | Jul 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Jan 2020 | Apr 2020 | Jul 2020 | Jan 2021 | Apr 2021 | Jul 2021 | Dec 2021 | Apr 2022 | Jul 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Jan 2025 | Mar 2025 | Apr 2025 | Jun 2025 | Jul 2025 | Sep 2025 | Dec 2025 | Jan 2026 | Mar 2026 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 176.20M | 201.20M | 191.20M | 185.70M | 195.80M | 196.70M | 200.10M | 197.00M | 171.20M | 177.10M | 203.50M | 211.20M | 198.80M | 214.70M | 214.50M | 205.60M | 228.20M | 232.20M | 190.00M | 206.20M | 209.10M | 199.80M | 212.90M | 212.90M | 203.00M | 203.00M | 228.90M | 209.60M | 209.60M | 216.00M | 216.00M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 136.20M | - | 135.50M | - | 151.10M | 139.80M | - | 143.40M | - |
| Gross Profit | 57.10M | 59.10M | 63.00M | 58.80M | 57.60M | 59.50M | 61.50M | 70.10M | 63.00M | 60.00M | 64.40M | 60.70M | 61.10M | 57.60M | 26.30M | 57.20M | 64.60M | 74.10M | 64.80M | 70.80M | 73.40M | 63.30M | 72.70M | 76.30M | 57.10M | 65.80M | 66.90M | 68.50M | 76.70M | 76.70M | 67.50M | 67.50M | 77.80M | 69.80M | 69.80M | 72.60M | 72.60M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 54.60M | - | 54.30M | - | 58.20M | 54.40M | - | 58.20M | - |
| Operating Income | 22.60M | 25.20M | 28.40M | 18.60M | 23.50M | 15.50M | 13.60M | 17.20M | 7.30M | 10.40M | 14.50M | 4.60M | 4.60M | 1.40M | -26.80M | 6.10M | 15.80M | 25.70M | 14.00M | 26.60M | 23.00M | 13.00M | 15.60M | 24.20M | 4.20M | 7.70M | 9.30M | 11.20M | 22.10M | 22.10M | 13.20M | -80.70M | 19.60M | 15.40M | 15.40M | 14.40M | 14.40M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 26.80M | - | -71.10M | - | 28.30M | 18.00M | - | 7.90M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.40M | - | 8.70M | - | 7.50M | 7.40M | - | 7.50M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.80M | - | -86.60M | - | 14.10M | 3.80M | - | -6.40M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.70M | - | 2.50M | - | 1.90M | 1.40M | - | 1.60M | - |
| Net Income | 14.10M | 14.70M | 17.60M | 11.10M | 15.00M | 10.60M | 11.30M | 12.20M | 3.80M | 3.00M | 5.80M | -1.40M | -1.30M | -1.90M | -28.30M | -6.40M | 3.10M | 12.00M | 1.40M | 7.60M | 8.20M | 3.10M | 4.10M | 9.10M | -500.00K | 1.40M | 1.40M | -300.00K | 6.90M | 6.90M | -89.10M | -89.10M | 12.20M | 2.30M | 2.30M | -8.10M | -8.10M |
| Diluted EPS | - | 0.39 | 0.47 | 0.29 | 0.40 | 0.28 | 0.30 | 0.32 | 0.10 | 0.08 | 0.15 | -0.04 | -0.03 | -0.05 | -0.73 | -0.16 | 0.08 | 0.29 | 0.03 | 0.18 | 0.20 | 0.08 | 0.10 | 0.21 | -0.01 | 0.03 | 0.03 | -0.01 | 0.17 | 0.17 | -2.15 | -2.15 | 0.29 | 0.05 | 0.05 | -0.19 | -0.19 |
| R&D Expense | 12.50M | 13.10M | 14.00M | 13.30M | 14.40M | 17.70M | 19.70M | 22.00M | 20.50M | 18.80M | 18.80M | 20.90M | 21.70M | 20.90M | 19.00M | 16.70M | 18.20M | 19.20M | 17.70M | 18.90M | 20.20M | 20.00M | 23.00M | 20.00M | 20.50M | 22.60M | 22.00M | 23.50M | - | 22.00M | - | 21.40M | - | - | 21.70M | - | 22.20M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Oct 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Oct 2020 | Oct 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 | Oct 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 632.30M | 620.10M | 698.10M | 773.40M | 780.60M | 738.30M | 818.10M | 859.40M | 893.40M | 811.00M | 844.60M | 844.60M |
| Cost of Revenue | - | - | - | - | - | - | - | 575.90M | 603.10M | 554.10M | 554.10M | - |
| Gross Profit | 250.60M | 248.40M | 253.50M | 253.90M | 256.70M | 190.20M | 271.50M | 283.50M | 290.30M | 256.90M | 290.50M | 290.50M |
| Operating Expenses | - | - | - | - | - | - | - | 195.30M | 213.20M | 224.80M | 224.40M | - |
| Operating Income | 127.50M | 109.10M | 83.70M | 44.50M | 45.70M | -33.70M | 74.10M | 88.20M | 77.10M | 32.10M | 66.10M | -27.80M |
| EBITDA | - | - | - | - | - | - | - | 114.50M | 91.20M | 62.90M | 700.00K | - |
| Interest Expense | - | - | - | - | - | - | - | 36.40M | 26.70M | 26.80M | 32.70M | - |
| Pretax Income | - | - | - | - | - | - | - | 44.50M | 31.30M | 5.00M | -59.20M | - |
| Tax Provision | - | - | - | - | - | - | - | 13.70M | -16.60M | 53.30M | 10.70M | - |
| Net Income | 80.00M | 68.50M | 51.60M | 27.50M | 15.50M | -57.90M | 17.40M | 30.30M | 47.40M | -48.80M | -70.30M | -70.30M |
| Diluted EPS | 2.12 | 1.82 | 1.36 | 0.72 | 0.40 | -1.49 | 0.43 | 0.73 | 1.08 | -1.17 | -1.70 | -1.70 |
| R&D Expense | 50.40M | 53.50M | 67.30M | 83.00M | 78.10M | 78.90M | 71.90M | 77.00M | 84.80M | 87.00M | - | 91.10M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2014 | Oct 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Oct 2020 | Sep 2021 | Oct 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 | Oct 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 622.40M | 1.04B | 987.90M | 1.04B | 1.14B | - | 1.15B | 1.18B | 1.25B | 1.21B | 1.11B | 1.11B |
| Current Assets | - | - | - | - | - | - | - | - | - | 609.90M | 658.30M | 649.90M | 641.80M | - |
| Cash & Equivalents | 500.00K | 20.60M | 36.50M | 83.30M | 51.90M | 29.90M | 100.60M | - | 144.60M | 89.40M | 152.60M | 168.70M | 145.00M | 145.00M |
| Inventory | - | - | - | - | - | - | - | - | - | 303.20M | 277.50M | 264.80M | 299.40M | - |
| Receivables | - | - | - | - | - | - | - | - | - | 173.30M | 163.60M | 157.70M | 156.60M | - |
| Total Liabilities | - | - | 86.10M | 649.90M | 548.50M | 580.20M | 673.70M | - | 651.00M | 637.70M | 668.60M | 670.40M | 620.80M | 620.80M |
| Current Liabilities | - | - | 77.80M | 151.80M | 152.00M | 175.10M | 160.60M | - | 166.60M | 173.10M | 162.80M | 195.90M | 187.20M | 187.20M |
| Long Term Debt | - | - | 0 | 463.90M | 364.80M | 364.40M | 452.80M | - | 431.70M | 412.30M | 441.10M | 397.10M | 366.00M | 366.00M |
| Total Debt | - | - | - | - | - | - | - | - | - | 436.40M | 469.50M | 470.40M | 395.90M | - |
| Total Equity | 359.30M | 495.60M | 526.00M | 379.00M | 426.20M | 444.90M | 451.70M | - | 483.30M | 533.40M | 567.70M | 529.10M | 472.60M | 472.60M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | 40.09M | 40.53M | 41.09M | 41.69M | - |
Cash Flows (Annual)
Figures in USD.
| Metric | Oct 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Oct 2020 | Sep 2021 | Oct 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 | Oct 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 85.20M | 74.20M | 75.20M | 85.30M | 71.90M | 13.20M | - | 92.60M | 16.90M | 108.40M | 47.30M | 41.70M | 41.70M |
| Investing Cash Flow | -102.10M | -21.60M | -292.00M | -25.20M | -93.20M | -26.90M | - | -16.20M | -48.40M | -44.90M | -27.50M | 10.30M | 10.30M |
| Financing Cash Flow | 36.70M | -36.80M | 263.30M | -90.40M | -100.00K | 83.60M | - | -32.30M | -23.80M | -200.00K | -3.30M | -75.90M | -75.90M |
| Capital Expenditure | -34.30M | -28.90M | -20.20M | -20.40M | -19.80M | -23.50M | - | -15.10M | -21.30M | -20.70M | -26.90M | -22.90M | -22.90M |
| Free Cash Flow | 50.90M | 45.30M | 55.00M | 64.90M | 52.10M | -10.30M | - | 77.50M | -4.40M | 87.70M | 20.40M | 18.80M | 18.80M |
| Net Change in Cash | - | - | - | - | - | - | - | - | -55.30M | 63.30M | 16.50M | -23.90M | - |
Ratios (Annual)
Figures in %.
| Metric | Oct 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Oct 2020 | Oct 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 | Oct 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 39.6% | 40.1% | 36.3% | 32.8% | 32.9% | 25.8% | 33.2% | 33.0% | 32.5% | 31.7% | 34.4% | 34.4% |
| Operating Margin % | 20.2% | 17.6% | 12.0% | 5.8% | 5.9% | -4.6% | 9.1% | 10.3% | 8.6% | 4.0% | 7.8% | -3.3% |
| Net Margin % | 12.7% | 11.0% | 7.4% | 3.6% | 2.0% | -7.8% | 2.1% | 3.5% | 5.3% | -6.0% | -8.3% | -8.3% |
| ROE % | 16.1% | 13.0% | 13.6% | 6.5% | 3.5% | -12.8% | 3.6% | 5.7% | 8.3% | -9.2% | -14.9% | -14.9% |
| ROCE % | - | 20.0% | 9.4% | 5.3% | 5.3% | -3.4% | 7.6% | 8.7% | 7.1% | 3.2% | 7.2% | -3.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Pzena Investment Management LLC | 10.32% | 4.34M | $80.20M |
| 2 | Blackrock Inc. | 9.25% | 3.89M | $71.90M |
| 3 | Allspring Global Investments Holdings, LLC | 5.43% | 2.28M | $42.16M |
| 4 | Neuberger Berman Group, LLC | 4.95% | 2.08M | $38.44M |
| 5 | LSV Asset Management | 4.44% | 1.87M | $34.52M |
| 6 | Vanguard Capital Management LLC | 4.44% | 1.87M | $34.47M |
| 7 | Rice, Hall, James & Associates LLC | 3.43% | 1.45M | $26.69M |
| 8 | Acadian Asset Management. LLC | 2.71% | 1.14M | $21.06M |
| 9 | State Street Corporation | 2.65% | 1.12M | $20.61M |
| 10 | Geode Capital Management, LLC | 2.61% | 1.10M | $20.27M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VREX
Varex Imaging Corporation Estimates – NASDAQ:VREX - TradingView
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE9JSDJCa3pVMm5xY1lhVGJyWHVFOXV1c09sNWtOckhDT1RSemFyazdydTZqNU1faTlZd3NIR05XNlRCQ3JqVXViaE5xdDFRSS00ZW56ODJKZmpQcm5jTjFRSUxJZGFtRXFyLXJ0M2V4S1lMUUdJREpyOA?oc=5" target="_blank">Varex…
VREX 8-K & SEC Filings - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBVekZ4UW5Za253RThDaDd3Q2hSQ0J5aHk5MHdXSzk5dFdXSEZ3MU9pa0lhQWlPQjNaRDRpS3h3U0VCOFNiYm1vV1R3eVlmcWxhd2otcW9UaGpZUVNscWMtVlBNZGhrdWhkUmdlWi12dFg0UFV4SWlhOXBn?oc=5" target="_blank">VRE…
VREX 261016 10.00P (VREX261016P10000) Stock Options Chain | Quotes & News - Moomoo
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1STGVKMldKdDhQZ1Nmd3dqa1hOSVB5TlIyaW1SUG92OHczLVNjMzlSTEJFQ0otTjNmZ29Rd1V6bjVuUWpWNnpLRGpZejNXLWU3VjVTeGI2U05iOVl2ekc4?oc=5" target="_blank">VREX 261016 10.00P (VREX261016P10000) S…
SHAREHOLDER ALERT - The M&A Class Action Firm Is Investigating the Merger - BWMN, DV, VREX and HZO - IS IT A FAIR DEAL FOR YOU? - Morningstar
<a href="https://news.google.com/rss/articles/CBMiigJBVV95cUxOdERxV08tSmkxSUowOFZKSnBaR3RJZDlVelJzOTNIZlRSVEkxR1NFUmtaZ2pPYnVtZEpSdXZ1U1NsOXNvZ0l6SmREZ2dLQU9vNHE4NFVZTTFSWTJVWDB2VHV3WlJORkhvajJHXzRDcDBtVlZ3TExwZDdheEpHSnVmOUMzWDhDdTNnRjlkaG…
Ahead of an October 28 vote, Varex Imaging (VREX) expands details on its proposed Teledyne merger. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNRkNJTjZSc3JMdDNQREx6eEhkLVVCMnZfRy00cFM0WGR3c19HSGMtcVZPNTZydHZ2M1M1akQ5TEh3NmlsMm9DS0lITVJSTlJERlU5Y2gwa055VXFFb2xGelUtVmthRTdqNVltaWE1MlhTYTdkU2lIaTdFZzFVSXFlMm92bWwwOHFPMkNzSm…
Deal Valued At $1.1 Billion Sends This X-Ray Stock Soaring 48% - Investor's Business Daily
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxPVUtha0FyQXhQNURjZlZwV25uRVFkTHMyNTVrYjlnTXJSX29ZbVEtZzRKQW5FZ2Jub0kxMjkxcGlnYk5sR3FmNGxobWtZRE9LMElJRC1Da3o1ZDJ5eU5OZ3FoMU1rZFBMMXNRR1otRTl5NDcyc0k0UGV1SmMtYmVab1F2REZRWGdyQkE?oc…
VREX — Frequently Asked Questions
What is the current share price of Varex Imaging Corporation (VREX)?
As of 2026-10-23 16:27 PDT, Varex Imaging Corporation (VREX) trades at $18.42 on NasdaqGS. Its 52-week range is $9.32 to $18.58.
What is the market capitalisation of VREX?
Varex Imaging Corporation (VREX) has a market capitalisation of $776.37M on NasdaqGS.
What is the P/E ratio of VREX?
VREX trades at a trailing price-to-earnings (P/E) ratio of 34.75. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 1.57.
What is the return on equity (ROE) of VREX?
VREX has a return on equity (ROE) of 4.59%. Its return on capital employed (ROCE) is -3.02%.
Is VREX a good stock to buy?
This page provides a data-driven analysis of Varex Imaging Corporation (VREX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.